Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04523701

Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection (BiLe -Trial)

Bile leakage (BL) is the most frequent complication after liver resection. This study is to investigate the role of intraoperative administration of SMOFlipid 20% (fat emulsion which allows intraoperative identification of open bile ducts at the liver resection surface when it is administered retrograde through the cystic duct) in terms of prevention of postoperative BL within 30 days after surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Department of Visceral Surgery, Cantonal Hospital of Aarau, Aarau, Switzerland

Loading trial locations.

About this study

Bile leakage (BL) is the most frequent complication after liver resection leading to the need of interventional drainage, endoscopic retrograde cholangio pancreatography (ERCP) or even reoperation. Strategies leading to a reduction of the rate of this complication are valuable. SMOFlipid 20% is a fat emulsion which is primary indicated for parenteral nutrition. Because of its fatty content this solution is white. This allows the clear intraoperative identification of open bile ducts at the liver resection surface when it is administered retrograde through the cystic duct. Consequently, open bile ducts can be sutured preventing the postoperative development of BL. If the rate of bile leakages can be reduced, resources for interventions and relaparotomy will be saved. This study is to investigate intraoperative administration of SMOFlipid 20% in terms of prevention of BL within 30 days after surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who will receive an anatomical resection of two or more liver segments for any reason with simultaneous cholecystectomy in elective Setting
  • Patients who will receive an anatomical resection of two or more liver segments for any reason which already had a cholecystectomy if intraoperatively the cystic stump can be identified and opened
  • Ability of subject to understand character and individual consequences of the clinical Trial
  • Informed consent documented by signature

Exclusion criteria

  • Previous cholecystectomy if intraoperative it is not possible to identify the cystic stump
  • Intraoperative hepatico-jejunostomy
  • Hypersensitivity to fish-, egg-, soybean or peanut protein or to any of the active ingredients or excipients
  • Immunosuppression, pregnancy
  • Emergency liver resection because of traumatic liver rupture
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Treatment and study plan

"white" test" (= the administration of SMOFlipid retrograde through the cystic duct)

Drug

"white" test" (= the administration of SMOFlipid retrograde through the cystic duct)

Primary outcomes

  1. rate of postoperative bile leakage

    Time frame: within 30 days postoperative

    Comparison of the rate of postoperative bile leakage in the control and in the intervention group. This is a binary endpoint defined by the presence or absence of the bile leakage (yes or no). Bile leakage is defined as bilirubin concentration in the drain fluid at least 3 times the serum bilirubin concentration on or after postoperative day 3.

Secondary outcomes

  1. Severity of the bile leakage (Grade A, B or C according to the definition by Koch et al).

    Time frame: within 30 days postoperative

    The severity of bile leakage is classified according to its impact on patients´ clinical management. Grade A bile leakage causes no change in patients' clinical management. A Grade B bile leakage requires active therapeutic intervention but is manageable without relaparotomy, whereas in Grade C bile leakage relaparotomy is required.

  2. In-hospital mortality other than related to the bile leakage

    Time frame: within 30 days postoperative

    In-hospital mortality other than related to the bile leakage

  3. In-Hospital morbidity other than related to the bile leakage

    Time frame: within 30 days postoperative

    In-Hospital morbidity other than related to the bile leakage

  4. Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)

    Time frame: within 30 days postoperative

    Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)

  5. Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)

    Time frame: within 30 days postoperative

    Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)

  6. Interventional drainage (yes/no)

    Time frame: within 30 days postoperative

    Interventional drainage (yes/no)

  7. Re-operation (yes/no)

    Time frame: within 30 days postoperative

    Re-operation (yes/no)

  8. Intensive care unit (ICU) stay (in days)

    Time frame: within 30 days postoperative

    Intensive care unit (ICU) stay (in days)

  9. Total hospital stay (in days)

    Time frame: within 30 days postoperative

    Total hospital stay (in days)

Study contacts

Contact information is provided by the study sponsor or research team.

Giulia Manzini, Dr. med.

CONTACT

[email protected]

+41-62-8389734

Sponsors and collaborators

Lead sponsor

Giulia Manzini

Other

Registry information

Official study title

Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection- A Randomized Controlled Multicentric Superiority Trial- The BiLe-Trial (Bile Leakage Trial)

Acronym: BiLe

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Aug 24, 2020
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.